Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8687888990919293949596...123124»
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 30, 2021   
    P1/2,  N=40, Recruiting, 
    However, our data suggest that QoL could be restored after 12 months; this trend might partly reflect the impact of therapy optimisation. Not yet recruiting --> Recruiting | N=20 --> 40 | Trial completion date: Nov 2021 --> Oct 2022 | Trial primary completion date: Nov 2021 --> Jul 2022
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Enrollment closed:  A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Mar 29, 2021   
    P1b,  N=77, Active, not recruiting, 
    Not yet recruiting --> Recruiting | N=20 --> 40 | Trial completion date: Nov 2021 --> Oct 2022 | Trial primary completion date: Nov 2021 --> Jul 2022 Recruiting --> Active, not recruiting
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Clinical Outcomes for Advanced Hepatocellular Carcinoma Patients Treated With Systemic Agents in Real-World Practice () -  Mar 28, 2021 - Abstract #NCCN2021NCCN_105;    
    Despite the fact that patients with a Child Pugh score of B are traditionally excluded from HCC clinical trials, some patients with these characteristics may still benefit from systemic therapy. We need further large-scale prospective studies in this patient population to further determine the safety and survival benefits, and to determine which systemic agent is best to use first-line in advanced HCC patients with Child Pugh B liver function.
  • ||||||||||  temozolomide / Generic mfg.
    [VIRTUAL] Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_3260;    
    He had been recently treated with 6 monthly octreotide injections and maximal dose cinacalcet for gradually rising Ca/PTH levels...Anti-PTH immunotherapy and Lutathera are promising but require further investigation...Anti-angiogenic TKI's (sorafenib, lenvatinib) have been used with varying success...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Clinical guideline, Journal:  Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline. (Pubmed Central) -  Mar 26, 2021   
    Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. Antiviral treatment is recommended in individuals with advanced hcc who are positive for the hepatitis B surface antigen.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer. (Pubmed Central) -  Mar 25, 2021   
    In the current study, which focused on surgical interventions performed on patients undergoing lenvatinib treatment, 1 in 14 wound complications improved conservatively. However, it is critical to recognize that disease progression may occur if drugs are withdrawn prior to performing invasive procedures.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy:  Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer (clinicaltrials.gov) -  Mar 25, 2021   
    P2,  N=30, Recruiting, 
    However, it is critical to recognize that disease progression may occur if drugs are withdrawn prior to performing invasive procedures. Trial completion date: Mar 2021 --> Feb 2022 | Trial primary completion date: Jan 2021 --> Feb 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Mar 21, 2021   
    P2,  N=50, Recruiting, 
    Complete MVTT necrosis may allow downstaging and subsequent eligibility for surgical resection in a proportion of patients with advanced HCC. Not yet recruiting --> Recruiting
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Clinical data, Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. (Pubmed Central) -  Mar 19, 2021   
    Thus, tumor immunotherapy using PD-1/PD-L1 blockers exhibits promising outcomes for the treatment of HCC, and more novel PD-1/PD-L1 inhibitors are being developed to fight against this disease. The present review discusses the clinical results and influencing factors of PD-1/PD-L1 inhibitors in HCC to provide insight into the development and optimization of PD-1/PD-L1 inhibitors in the treatment of HCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. (Pubmed Central) -  Mar 16, 2021   
    Further guidance on choosing between therapy options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.